I'll second that A :
And there are a number of potentials:
Othepedics
Intravenous
MSC (Crohns/GVHD)
Japan (excluding JCR)
According to MSB website , we currently have 2 partnered (Teva ;JCR)
The comment by Jason below re a potential 3rd partnering for a P2 application is interesting as I always envisaged the 3rd deal to be P3 Orthopedics (spinal fusion).
If anyone has access to Jason's note - it would be interesting to understand what P2 application he is referring to ?
Good luck all.
Jason Zhang, Edison Investment Research (5/27/14) "Mesoblast Ltd. intends to initiate a Phase 3 trial of mesenchymal precursor cells in discogenic low back pain later this year, following the successful Phase 2 trial that reported in February. . .now a leading contender in the field, Mesoblast could have five active programs in Phase 3 (two partnered) and four in Phase 2 studies (one partnered) with nine clinical candidates by the end of this year. We expect CEP-41750 to become the leading stem cell therapy for congestive heart failure."
- Forums
- ASX - By Stock
- MSB
- Ann: Appendix 4C - quarterly
Ann: Appendix 4C - quarterly, page-5
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.07 |
Change
-0.055(4.89%) |
Mkt cap ! $1.221B |
Open | High | Low | Value | Volume |
$1.14 | $1.16 | $1.06 | $8.816M | 8.055M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 280000 | $1.07 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.07 | 2000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 280000 | 1.065 |
5 | 149799 | 1.060 |
9 | 124023 | 1.055 |
14 | 191984 | 1.050 |
8 | 134232 | 1.045 |
Price($) | Vol. | No. |
---|---|---|
1.070 | 2000 | 1 |
1.075 | 19000 | 2 |
1.080 | 48905 | 3 |
1.085 | 28905 | 1 |
1.090 | 61845 | 5 |
Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |